Fiji

Fiji

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
3.63 (3.15 - 4.10) 2019 Modelled IHME
4.02 (3.52 - 4.44) 2018 Modelled IHME
4.25 (3.66 - 4.79) 2017 Modelled IHME
4.32 (3.78 - 4.83) 2016 Modelled IHME
4.38 (3.82 - 4.96) 2015 Modelled IHME
4.48 (3.91 - 5.03) 2014 Modelled IHME
4.6 (3.99 - 5.18) 2013 Modelled IHME
4.75 (4.08 - 5.33) 2012 Modelled IHME
4.89 (4.16 - 5.47) 2011 Modelled IHME
5.02 (4.24 - 5.65) 2010 Modelled IHME
5.15 (4.41 - 5.80) 2009 Modelled IHME
5.3 (4.56 - 5.98) 2008 Modelled IHME
5.44 (4.72 - 6.15) 2007 Modelled IHME
5.54 (4.81 - 6.29) 2006 Modelled IHME
5.58 (4.83 - 6.34) 2005 Modelled IHME
5.56 (4.83 - 6.30) 2004 Modelled IHME
5.52 (4.78 - 6.25) 2003 Modelled IHME
5.47 (4.71 - 6.20) 2002 Modelled IHME
5.43 (4.61 - 6.16) 2001 Modelled IHME
5.41 (4.56 - 6.17) 2000 Modelled IHME
5.51 (4.67 - 6.25) 1999 Modelled IHME
5.76 (4.91 - 6.54) 1998 Modelled IHME
6.07 (5.21 - 6.95) 1997 Modelled IHME
6.37 (5.46 - 7.34) 1996 Modelled IHME
6.59 (5.61 - 7.62) 1995 Modelled IHME
6.73 (5.69 - 7.72) 1994 Modelled IHME
6.86 (5.72 - 7.86) 1993 Modelled IHME
6.97 (5.78 - 7.97) 1992 Modelled IHME
7.06 (5.80 - 8.10) 1991 Modelled IHME
7.12 (5.77 - 8.22) 1990 Modelled IHME
2.22 (1.56 - 2.94) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.47 (0.34 - 0.58) 2019 Modelled IHME
0.51 (0.38 - 0.62) 2018 Modelled IHME
0.54 (0.39 - 0.68) 2017 Modelled IHME
0.56 (0.40 - 0.71) 2016 Modelled IHME
0.58 (0.40 - 0.75) 2015 Modelled IHME
0.62 (0.41 - 0.80) 2014 Modelled IHME
0.66 (0.43 - 0.86) 2013 Modelled IHME
0.71 (0.46 - 0.92) 2012 Modelled IHME
0.76 (0.50 - 0.98) 2011 Modelled IHME
0.81 (0.53 - 1.06) 2010 Modelled IHME
0.88 (0.58 - 1.13) 2009 Modelled IHME
0.96 (0.64 - 1.24) 2008 Modelled IHME
1.03 (0.70 - 1.33) 2007 Modelled IHME
1.09 (0.75 - 1.41) 2006 Modelled IHME
1.11 (0.76 - 1.44) 2005 Modelled IHME
1.09 (0.75 - 1.40) 2004 Modelled IHME
1.03 (0.71 - 1.32) 2003 Modelled IHME
0.95 (0.65 - 1.23) 2002 Modelled IHME
0.89 (0.60 - 1.17) 2001 Modelled IHME
0.87 (0.58 - 1.16) 2000 Modelled IHME
0.89 (0.60 - 1.17) 1999 Modelled IHME
0.95 (0.64 - 1.23) 1998 Modelled IHME
1.04 (0.69 - 1.33) 1997 Modelled IHME
1.14 (0.76 - 1.44) 1996 Modelled IHME
1.24 (0.83 - 1.59) 1995 Modelled IHME
1.35 (0.89 - 1.72) 1994 Modelled IHME
1.48 (0.97 - 1.89) 1993 Modelled IHME
1.63 (1.06 - 2.10) 1992 Modelled IHME
1.79 (1.15 - 2.33) 1991 Modelled IHME
1.97 (1.25 - 2.58) 1990 Modelled IHME
0.34 (0.21 - 0.52) 2015 Modelled WHO
0 2008 Survey/reported WHO WPRO, Woodring J et al, 2017
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
51 (42 - 61) 2019 Modelled IHME
52 (43 - 62) 2018 Modelled IHME
52 (43 - 62) 2017 Modelled IHME
52 (43 - 62) 2016 Modelled IHME
52 (43 - 62) 2015 Modelled IHME
53 (43 - 62) 2014 Modelled IHME
53 (43 - 63) 2013 Modelled IHME
53 (44 - 62) 2012 Modelled IHME
53 (44 - 62) 2011 Modelled IHME
53 (44 - 62) 2010 Modelled IHME
53 (44 - 62) 2009 Modelled IHME
53 (44 - 62) 2008 Modelled IHME
53 (44 - 62) 2007 Modelled IHME
53 (44 - 62) 2006 Modelled IHME
53 (44 - 62) 2005 Modelled IHME
52 (43 - 62) 2004 Modelled IHME
52 (43 - 61) 2003 Modelled IHME
52 (43 - 61) 2002 Modelled IHME
52 (43 - 62) 2001 Modelled IHME
52 (43 - 62) 2000 Modelled IHME
53 (44 - 62) 1999 Modelled IHME
53 (44 - 62) 1998 Modelled IHME
53 (45 - 62) 1997 Modelled IHME
54 (45 - 63) 1996 Modelled IHME
54 (46 - 63) 1995 Modelled IHME
54 (46 - 64) 1994 Modelled IHME
55 (46 - 64) 1993 Modelled IHME
55 (46 - 64) 1992 Modelled IHME
55 (46 - 64) 1991 Modelled IHME
55 (46 - 64) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
90 2018 Survey/reported WHO/UNICEF
90 2017 Survey/reported WHO/UNICEF
90 2016 Survey/reported WHO/UNICEF
90 2015 Survey/reported WHO/UNICEF
90 2014 Survey/reported WHO/UNICEF
90 2013 Survey/reported WHO/UNICEF
90 2012 Survey/reported WHO/UNICEF
90 2011 Survey/reported WHO/UNICEF
90 2010 Survey/reported WHO/UNICEF
90 2009 Survey/reported WHO/UNICEF
90 2008 Survey/reported WHO/UNICEF
90 2007 Survey/reported WHO/UNICEF
90 2006 Survey/reported WHO/UNICEF
90 2005 Survey/reported WHO/UNICEF
86 2004 Survey/reported WHO/UNICEF
96 2003 Survey/reported WHO/UNICEF
95 2002 Survey/reported WHO/UNICEF
99 2001 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
99 2018 Survey/reported WHO/UNICEF
99 2017 Survey/reported WHO/UNICEF
99 2016 Survey/reported WHO/UNICEF
99 2015 Survey/reported WHO/UNICEF
99 2014 Survey/reported WHO/UNICEF
99 2013 Survey/reported WHO/UNICEF
99 2012 Survey/reported WHO/UNICEF
99 2011 Survey/reported WHO/UNICEF
99 2010 Survey/reported WHO/UNICEF
99 2009 Survey/reported WHO/UNICEF
99 2008 Survey/reported WHO/UNICEF
99 2007 Survey/reported WHO/UNICEF
99 2006 Survey/reported WHO/UNICEF
99 2005 Survey/reported WHO/UNICEF
99 2004 Survey/reported WHO/UNICEF
99 2003 Survey/reported WHO/UNICEF
99 2002 Survey/reported WHO/UNICEF
98 2001 Survey/reported WHO/UNICEF
98 2000 Survey/reported WHO/UNICEF
98 1999 Survey/reported WHO/UNICEF
98 1998 Survey/reported WHO/UNICEF
98 1997 Survey/reported WHO/UNICEF
90 1996 Survey/reported WHO/UNICEF
82 1995 Survey/reported WHO/UNICEF
60 1994 Survey/reported WHO/UNICEF
88 1993 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
Yes
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.79 (0.63 - 0.98) 2019 Modelled IHME
0.79 (0.63 - 0.99) 2018 Modelled IHME
0.79 (0.63 - 0.98) 2017 Modelled IHME
0.78 (0.62 - 0.96) 2016 Modelled IHME
0.77 (0.61 - 0.95) 2015 Modelled IHME
0.77 (0.61 - 0.95) 2014 Modelled IHME
0.76 (0.61 - 0.94) 2013 Modelled IHME
0.76 (0.60 - 0.94) 2012 Modelled IHME
0.76 (0.60 - 0.94) 2011 Modelled IHME
0.75 (0.60 - 0.94) 2010 Modelled IHME
0.74 (0.59 - 0.92) 2009 Modelled IHME
0.73 (0.58 - 0.90) 2008 Modelled IHME
0.72 (0.57 - 0.88) 2007 Modelled IHME
0.7 (0.56 - 0.87) 2006 Modelled IHME
0.7 (0.55 - 0.87) 2005 Modelled IHME
0.7 (0.56 - 0.86) 2004 Modelled IHME
0.7 (0.56 - 0.87) 2003 Modelled IHME
0.7 (0.57 - 0.86) 2002 Modelled IHME
0.71 (0.57 - 0.86) 2001 Modelled IHME
0.71 (0.57 - 0.86) 2000 Modelled IHME
0.72 (0.58 - 0.87) 1999 Modelled IHME
0.73 (0.59 - 0.89) 1998 Modelled IHME
0.74 (0.60 - 0.91) 1997 Modelled IHME
0.76 (0.60 - 0.93) 1996 Modelled IHME
0.77 (0.61 - 0.94) 1995 Modelled IHME
0.77 (0.61 - 0.95) 1994 Modelled IHME
0.77 (0.61 - 0.96) 1993 Modelled IHME
0.77 (0.62 - 0.96) 1992 Modelled IHME
0.78 (0.61 - 0.97) 1991 Modelled IHME
0.78 (0.61 - 0.98) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
21 (14 - 28) 2019 Modelled IHME
20 (14 - 28) 2018 Modelled IHME
20 (14 - 27) 2017 Modelled IHME
20 (14 - 28) 2016 Modelled IHME
20 (13 - 28) 2015 Modelled IHME
20 (14 - 28) 2014 Modelled IHME
20 (13 - 28) 2013 Modelled IHME
20 (14 - 28) 2012 Modelled IHME
20 (14 - 27) 2011 Modelled IHME
20 (13 - 27) 2010 Modelled IHME
20 (14 - 27) 2009 Modelled IHME
20 (14 - 27) 2008 Modelled IHME
20 (14 - 27) 2007 Modelled IHME
20 (14 - 27) 2006 Modelled IHME
20 (14 - 27) 2005 Modelled IHME
21 (14 - 28) 2004 Modelled IHME
21 (14 - 28) 2003 Modelled IHME
21 (14 - 28) 2002 Modelled IHME
21 (14 - 28) 2001 Modelled IHME
21 (14 - 28) 2000 Modelled IHME
21 (14 - 28) 1999 Modelled IHME
21 (14 - 28) 1998 Modelled IHME
20 (14 - 28) 1997 Modelled IHME
20 (14 - 27) 1996 Modelled IHME
20 (14 - 27) 1995 Modelled IHME
20 (14 - 27) 1994 Modelled IHME
20 (14 - 27) 1993 Modelled IHME
20 (14 - 27) 1992 Modelled IHME
20 (14 - 27) 1991 Modelled IHME
20 (14 - 27) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
Yes
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
3.63 (%)
2019
(3.15 - 4.1(%))
IHME
HCV (RNA/cAg+)
0.79 (%)
2019
(0.63 - 0.98(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
51
2019
(37 - 68)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
31
2019
(22 - 42)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.47 (%)
2019, latest modelled
(0.34 - 0.58(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
90 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Yes
Eligible for HCV generic medicines

Partners